<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00703885</url>
  </required_header>
  <id_info>
    <org_study_id>UCSD IRB 060407 - A</org_study_id>
    <secondary_id>R01MH075792</secondary_id>
    <nct_id>NCT00703885</nct_id>
  </id_info>
  <brief_title>PharmacofMRI (Functional Magnetic Resonance Imaging) of Anxiolytic Medications (Alprazolam)</brief_title>
  <official_title>PharmacofMRI of Anxiolytic Medications (Alprazolam)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to use functional magnetic resonance imaging (fMRI) in healthy
      controls to examine the acute effects of certain anxiolytic medications on brain function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Increased amygdala and insula activity have been implicated in neurobiological models of
      anxiety. Using fMRI, the anxiolytic medication, lorazepam, has previously been found to
      decrease activation in these areas during the processing of emotional stimuli. This study
      aims to replicate those results but by using a different medication, alprazolam. An eventual
      aim of this study, in combination with future studies, is to evaluate the utility of fMRI as
      a tool to identify anxiolytic function in both established and novel compounds that may be
      used to treat anxiety.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of Alprazolam Versus Placebo on BOLD fMRI During Emotion Processing</measure>
    <time_frame>Same Day</time_frame>
    <description>Analysis not completed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Voxelwise Brain Imaging Data</measure>
    <time_frame>Post-Rx Administration</time_frame>
    <description>Analysis of data not completed.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Anxiety Disorders</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.25 mg alprazolam PO (liquid) will be administered 1 hour prior to fMRI scan.
One-time, single dose.
Note that subjects receive all 3 treatments in randomized order (cross-over study), approximately 7-10 days apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 mg alprazolam PO (liquid) will be administered 1 hour prior to fMRI scan
One-time, single dose.
Note that subjects receive all 3 treatments in randomized order (cross-over study), approximately 7-10 days apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Inactive ingredient in liquid matching appearance and volume of the two active alprazolam dose comparators.
Note that subjects receive all 3 treatments in randomized order (cross-over study), approximately 7-10 days apart.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.25 mg alprazolam</intervention_name>
    <description>0.25 mg alprazolam PO (liquid) to be administered 1 hour prior to fMRI scan
Note that subjects receive all 3 treatments in randomized order (cross-over study), approximately 7-10 days apart.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Xanax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1.0 mg alprazolam</intervention_name>
    <description>1 mg alprazolam PO (liquid) will be administered 1 hour prior to fMRI scan
Note that subjects receive all 3 treatments in randomized order (cross-over study), approximately 7-10 days apart.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Xanax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo (liquid) to be administered 1 hour prior to fMRI scan
Note that subjects receive all 3 treatments in randomized order (cross-over study), approximately 7-10 days apart.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male, or female (not pregnant or intending to become pregnant during the study)

          -  Between the ages of 18-30.

          -  In good general health.

          -  No specific contraindications to the drug being administered

        Exclusion Criteria:

          -  Subjects with a history of DSM-IV depressive disorder, psychotic disorder, anxiety
             disorder

          -  Subjects who meet criteria for substance abuse or dependence within the last 6 months

          -  Subjects with an positive urine screen for illicit drugs

          -  having clinically significant abnormal laboratory, ECG or physical examination
             findings not resolved by the baseline visit

          -  Patients who have taken psychotropic drugs or antidepressants (including monoamine
             oxidase inhibitors, MAOI's) within the last year

          -  subject is left-handed.

          -  The subject suffers from claustrophobia, or phobia for injections or blood.

          -  Magnetic Resonance Imaging related exclusion criteria: cardiac pacemaker, metal
             fragments in eyes/skin/body (shrapnel), subjects who have ever been a metal
             worker/welder; history of eye surgery/eyes washed out because of metal,
             aortic/aneurysm clips, prosthesis, by-pass surgery/coronary artery clips, hearing aid,
             heart valve replacement, subjects who are in the first trimester of pregnancy,
             subjects with an I.U.D. (birth control device), a shunt (ventricular or spinal),
             electrodes, metal plates/pins/screws/wires, or neuro/bio-stimulators (TENS unit).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Murray B Stein, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Simmons AN, Arce E, Lovero KL, Stein MB, Paulus MP. Subchronic SSRI administration reduces insula response during affective anticipation in healthy volunteers. Int J Neuropsychopharmacol. 2009 Sep;12(8):1009-20. doi: 10.1017/S1461145709990149. Epub 2009 Jun 23.</citation>
    <PMID>19545475</PMID>
  </reference>
  <reference>
    <citation>Aupperle RL, Ravindran L, Tankersley D, Flagan T, Stein NR, Simmons AN, Stein MB, Paulus MP. Pregabalin influences insula and amygdala activation during anticipation of emotional images. Neuropsychopharmacology. 2011 Jun;36(7):1466-77. doi: 10.1038/npp.2011.32. Epub 2011 Mar 23.</citation>
    <PMID>21430645</PMID>
  </reference>
  <reference>
    <citation>Aupperle RL, Tankersley D, Ravindran LN, Flagan T, Stein NR, Stein MB, Paulus MP. Pregabalin effects on neural response to emotional faces. Front Hum Neurosci. 2012 Mar 27;6:42. doi: 10.3389/fnhum.2012.00042. eCollection 2012.</citation>
    <PMID>22470326</PMID>
  </reference>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2008</study_first_submitted>
  <study_first_submitted_qc>June 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2008</study_first_posted>
  <results_first_submitted>June 19, 2013</results_first_submitted>
  <results_first_submitted_qc>December 19, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 22, 2014</results_first_posted>
  <last_update_submitted>December 19, 2014</last_update_submitted>
  <last_update_submitted_qc>December 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 22, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Murray B. Stein</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>functional magnetic resonance imaging</keyword>
  <keyword>fMRI</keyword>
  <keyword>alprazolam</keyword>
  <keyword>anxiety disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alprazolam</mesh_term>
    <mesh_term>Anti-Anxiety Agents</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>All subjects receive both doses of active drug and placebo in randomized order.</recruitment_details>
      <pre_assignment_details>All subjects receive both doses of active drug and placebo in randomized order.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ALL SUBJECTS RECEIVE ALL 3 TREATMENTS</title>
          <description>Alprazolam Low Dose Alprazolam High Dose Placebo
Sequence of administration not available for subjects</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ALL SUBJECTS RECEIVE ALL 3 TREATMENTS</title>
          <description>Alprazolam Low Dose Alprazolam High Dose Placebo
Please note that this is a cross-over design with all subjects receiving all three treatments</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Effect of Alprazolam Versus Placebo on BOLD fMRI During Emotion Processing</title>
        <description>Analysis not completed.</description>
        <time_frame>Same Day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BOLD fMRI</title>
            <description>Cross-over design. Each subject receives, on alternate days and in randomized fashion, either low dose, high dose, or placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Alprazolam Versus Placebo on BOLD fMRI During Emotion Processing</title>
          <description>Analysis not completed.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Voxelwise Brain Imaging Data</title>
        <description>Analysis of data not completed.</description>
        <time_frame>Post-Rx Administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Imaging Data for Repeated Measures</title>
            <description>Crossover design. Each subject receives, in randomized order and on different days:
Low dose alprazolam High dose alprazolam Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Voxelwise Brain Imaging Data</title>
          <description>Analysis of data not completed.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Acute effects within 2 hours of drug administration</time_frame>
      <desc>Acute, single-dose study</desc>
      <group_list>
        <group group_id="E1">
          <title>ALL SUBJECTS RECEIVE ALL 3 TREATMENTS</title>
          <description>Alprazolam Low Dose Alprazolam High Dose Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This is a single dose cross-over study in 16 healthy subjects.
BOLD fMRI analyses for this study were not completed by the investigators.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Murray B. Stein MD, MPH</name_or_title>
      <organization>UCSD</organization>
      <phone>858-534-6451</phone>
      <email>mstein@ucsd.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

